SCHEMBL477271

SCHEMBL477271

FC(F)n1cnc2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
HPGD P15428 1/20 0.58
KMT2A Q03164 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.48
HTT P42858 2/20 0.47
HDAC8 Q9BY41 1/20 0.44
POLB P06746 1/20 0.43
TNF P01375 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
FGFR1 P11362 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
STAT6 P42226 1/20 0.41
ALDH3A1 P30838 1/20 0.40
GGPS1 O95749 1/20 0.40
FDPS P14324 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28800551 0.89 MEN1 (0.49) MEN1HPGDKMT2AHSD17B10TDP1
Thiourea SCHEMBL28497498 0.89 MEN1 (0.53) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL9675201 0.84 MEN1 (0.64) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL6094420 0.79 HSD17B10 (0.58) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL1027011 0.79 HPGD (0.68) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL4785512 0.79 MEN1 (0.58) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL7514337 0.79 HSD17B10 (0.58) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL2146965 0.79 MEN1 (0.68) MEN1HPGDKMT2AHSD17B10TDP1
Hydrochloric Acid SCHEMBL9787788 0.78 HPGD (0.66) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL4233005 0.78 MEN1 (0.66) MEN1HPGDKMT2AHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114656405-A Preparation method of difluoromethylbenzimidazole 广州和为医药科技有限公司 2022-06-24 CN claimed
CN-119371444-A Difluoromethyl substituted imidazole carbene metal complex and preparation method and application thereof 中国人民大学 2025-01-28 CN disclosed
CN-117384140-B Benzimidazole derivative and application thereof 沈阳药科大学 2024-10-11 CN disclosed
CN-115960055-B N-difluoromethyl benzothiazole/oxazolselenone compound, and preparation method and application thereof 华南农业大学 2024-05-10 CN disclosed
CN-115466228-B N-difluoromethyl triazole selenourea compound with insecticidal, bactericidal and herbicidal functions and application thereof 华南农业大学 2024-05-10 CN disclosed
CN-117384140-A Benzimidazole derivative and application thereof 沈阳药科大学 2024-01-12 CN disclosed
CN-114685495-B N-difluoromethyl diazacyclo selenourea compound with insecticidal, bacteriostatic, herbicidal and anticancer effects and preparation and application thereof 华南农业大学 2023-08-04 CN disclosed
CN-115960055-A N-difluoromethyl benzothiazole/oxazole selenone compound and preparation method and application thereof 华南农业大学 2023-04-14 CN disclosed
CN-115466228-A N-difluoromethyl triazole selenourea compound with insecticidal, bactericidal and weeding functions and application thereof 华南农业大学 2022-12-13 CN disclosed
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 GBIOTECH S.À.R.L. (CH) 2022-09-01 US disclosed
US-20090105400-A1 Imidazolium side chains for example; for example polymers based on 1-methyl-3-(2H,9H,9H-perfluoro-3,6-dioxa-5-methyl-8-nonenyl)-imidazolium trifluoromethanesulfonate; polymer electrolytes for fuel cell, secondary battery, capacitor, dye-sensitized solar cell and electrochromic device DAIKIN INDUSTRIES, LTD. (JP) 2009-04-23 US disclosed
EP-1983008-A1 FLUORINE-CONTAINING POLYMER CONTAINING HETEROAROMATIC RING Daikin Industries, Ltd. (JP) 2008-10-22 EP disclosed
WO-2008032041-A1 PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST PI3K ENZYMES ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032060-A1 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032036-A1 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032033-A1 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
WO-2008032089-A1 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-03-20 WO disclosed
EP-1427408-A4 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) BRISTOL MYERS SQUIBB CO (US) 2005-10-26 EP disclosed
EP-1427408-A2 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2004-06-16 EP disclosed
WO-2003024899-A2 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 FFAR2, FFAR1, FFAR3 MEN1 4743/4885HPGD 1443/4885KMT2A 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.